Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate02: Saruparib in BRCAm Localised High-Risk Prostate Cancer
NCT06952803Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Mar 2033
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of saruparib in prostate cancer (PCa), sponsored by AstraZeneca. Started Aug 2025; status: recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06952803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952803.